Cabazitaxel: A New Treatment for Metastatic Castration-Resistant Prostate Cancer

American Journal of Lifestyle Medicine, 05/21/2012

The combination of cabazitaxel and prednisone is an important new treatment option for men with docetaxel–refractory metastatic castration–resistant prostate cancer (CRPC). However, this agent should be administered with close, appropriate monitoring, especially in men at high risk of neutropenia or diarrhea. Future research directions for this new agent will include exploring its role in combination with other agents and comparing with docetaxel for the first–line treatment of metastatic CRPC.

Print Article Summary Cat 2 CME Report